CL2020000175A1 - Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina. - Google Patents
Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina.Info
- Publication number
- CL2020000175A1 CL2020000175A1 CL2020000175A CL2020000175A CL2020000175A1 CL 2020000175 A1 CL2020000175 A1 CL 2020000175A1 CL 2020000175 A CL2020000175 A CL 2020000175A CL 2020000175 A CL2020000175 A CL 2020000175A CL 2020000175 A1 CL2020000175 A1 CL 2020000175A1
- Authority
- CL
- Chile
- Prior art keywords
- bst1
- antibodies against
- pharmaceutical combinations
- citadine
- ribosil
- Prior art date
Links
- 101150018516 BST1 gene Proteins 0.000 title 1
- 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 abstract 3
- 101000794082 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 abstract 3
- 101001099051 Homo sapiens GPI inositol-deacylase Proteins 0.000 abstract 3
- 101000855645 Camptotheca acuminata (S)-8-oxocitronellyl enol synthase CYC2 Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1711785.4A GB201711785D0 (en) | 2017-07-21 | 2017-07-21 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000175A1 true CL2020000175A1 (es) | 2020-06-12 |
Family
ID=59771583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000175A CL2020000175A1 (es) | 2017-07-21 | 2020-01-20 | Combinaciones farmacéuticas que comprenden anticuerpos contra bst1 y citadina. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20200231694A1 (enExample) |
| EP (1) | EP3655033A1 (enExample) |
| JP (1) | JP2020527594A (enExample) |
| KR (1) | KR20200032162A (enExample) |
| CN (1) | CN111132697A (enExample) |
| AR (1) | AR112460A1 (enExample) |
| AU (1) | AU2018303241A1 (enExample) |
| BR (1) | BR112020001320A2 (enExample) |
| CA (1) | CA3070264A1 (enExample) |
| CL (1) | CL2020000175A1 (enExample) |
| CO (1) | CO2020001792A2 (enExample) |
| EA (1) | EA202090333A1 (enExample) |
| GB (1) | GB201711785D0 (enExample) |
| IL (1) | IL272096A (enExample) |
| MA (1) | MA49627A (enExample) |
| MX (1) | MX2020000752A (enExample) |
| PH (1) | PH12020550024A1 (enExample) |
| SG (1) | SG11202000390TA (enExample) |
| TW (1) | TW201907952A (enExample) |
| UY (1) | UY37815A (enExample) |
| WO (1) | WO2019016371A1 (enExample) |
| ZA (1) | ZA202000881B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004063494A1 (de) * | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| NZ618503A (en) * | 2011-06-28 | 2016-03-31 | Oxford Biotherapeutics Ltd | Antibodies to adp-ribosyl cyclase 2 |
| GB201806084D0 (en) * | 2018-04-13 | 2018-05-30 | Berlin Chemie Ag | Antibodies |
| EP4045083B1 (en) * | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
-
2017
- 2017-07-21 GB GBGB1711785.4A patent/GB201711785D0/en not_active Ceased
-
2018
- 2018-07-20 CN CN201880060959.0A patent/CN111132697A/zh active Pending
- 2018-07-20 CA CA3070264A patent/CA3070264A1/en active Pending
- 2018-07-20 MA MA049627A patent/MA49627A/fr unknown
- 2018-07-20 WO PCT/EP2018/069768 patent/WO2019016371A1/en not_active Ceased
- 2018-07-20 SG SG11202000390TA patent/SG11202000390TA/en unknown
- 2018-07-20 JP JP2020503018A patent/JP2020527594A/ja not_active Withdrawn
- 2018-07-20 MX MX2020000752A patent/MX2020000752A/es unknown
- 2018-07-20 BR BR112020001320-0A patent/BR112020001320A2/pt not_active IP Right Cessation
- 2018-07-20 UY UY0001037815A patent/UY37815A/es not_active Application Discontinuation
- 2018-07-20 EP EP18746656.0A patent/EP3655033A1/en not_active Withdrawn
- 2018-07-20 AU AU2018303241A patent/AU2018303241A1/en not_active Abandoned
- 2018-07-20 TW TW107125058A patent/TW201907952A/zh unknown
- 2018-07-20 US US16/632,195 patent/US20200231694A1/en not_active Abandoned
- 2018-07-20 KR KR1020207005030A patent/KR20200032162A/ko not_active Withdrawn
- 2018-07-20 AR ARP180102042 patent/AR112460A1/es not_active Application Discontinuation
- 2018-07-20 EA EA202090333A patent/EA202090333A1/ru unknown
-
2020
- 2020-01-16 PH PH12020550024A patent/PH12020550024A1/en unknown
- 2020-01-16 IL IL272096A patent/IL272096A/en unknown
- 2020-01-20 CL CL2020000175A patent/CL2020000175A1/es unknown
- 2020-02-11 ZA ZA2020/00881A patent/ZA202000881B/en unknown
- 2020-02-18 CO CONC2020/0001792A patent/CO2020001792A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200231694A1 (en) | 2020-07-23 |
| ZA202000881B (en) | 2021-08-25 |
| EA202090333A1 (ru) | 2020-05-06 |
| CO2020001792A2 (es) | 2020-07-31 |
| MX2020000752A (es) | 2020-08-17 |
| GB201711785D0 (en) | 2017-09-06 |
| CA3070264A1 (en) | 2019-01-24 |
| AR112460A1 (es) | 2019-10-30 |
| SG11202000390TA (en) | 2020-02-27 |
| TW201907952A (zh) | 2019-03-01 |
| KR20200032162A (ko) | 2020-03-25 |
| CN111132697A (zh) | 2020-05-08 |
| AU2018303241A1 (en) | 2020-02-20 |
| PH12020550024A1 (en) | 2021-02-15 |
| BR112020001320A2 (pt) | 2020-08-11 |
| UY37815A (es) | 2019-02-28 |
| MA49627A (fr) | 2020-05-27 |
| WO2019016371A1 (en) | 2019-01-24 |
| EP3655033A1 (en) | 2020-05-27 |
| IL272096A (en) | 2020-03-31 |
| JP2020527594A (ja) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CL2018002359A1 (es) | Métodos para usar agonistas de fxr | |
| CL2017002904A1 (es) | Métodos y kits para tratar la depresión | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| CL2019002869A1 (es) | Inhibidores selectivos hdac6. | |
| SV2018005633A (es) | Derivados de heteroarilo como inhibidores de parp | |
| CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| MX2018015352A (es) | Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer. | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| ECSP19077969A (es) | Compuesto heterociclico | |
| CO2019007205A2 (es) | Usos terapéuticos de un polvo de insectos | |
| CL2016001756A1 (es) | Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular. | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| MX2021000363A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| BR112018016729A2 (pt) | novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| PE20161509A1 (es) | Sistemas, metodos y kits de limpieza de una region ocular | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| MX2019001577A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| CL2020000176A1 (es) | Pautas para el tratamiento de infecciones por el vih y sida. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. |